Literature DB >> 9585613

Haplotype and phenotype analysis of nine recurrent BRCA2 mutations in 111 families: results of an international study.

S L Neuhausen1, A K Godwin, R Gershoni-Baruch, E Schubert, J Garber, D Stoppa-Lyonnet, E Olah, B Csokay, O Serova, F Lalloo, A Osorio, M Stratton, K Offit, J Boyd, M A Caligo, R J Scott, A Schofield, E Teugels, M Schwab, L Cannon-Albright, T Bishop, D Easton, J Benitez, M C King, B A Ponder, B Weber, P Devilee, A Borg, S A Narod, D Goldgar.   

Abstract

Several BRCA2 mutations are found to occur in geographically diverse breast and ovarian cancer families. To investigate both mutation origin and mutation-specific phenotypes due to BRCA2, we constructed a haplotype of 10 polymorphic short tandem-repeat (STR) markers flanking the BRCA2 locus, in a set of 111 breast or breast/ovarian cancer families selected for having one of nine recurrent BRCA2 mutations. Six of the individual mutations are estimated to have arisen 400-2,000 years ago. In particular, the 6174delT mutation, found in approximately 1% of individuals of Ashkenazi Jewish ancestry, was estimated to have arisen 29 generations ago (1-LOD support interval 22-38). This is substantially more recent than the estimated age of the BRCA1 185delAG mutation (46 generations), derived from our analogous study of BRCA1 mutations. In general, there was no evidence of multiple origins of identical BRCA2 mutations. Our study data were consistent with the previous report of a higher incidence of ovarian cancer in families with mutations in a 3.3-kb region of exon 11 (the ovarian cancer cluster region [OCCR]) (P=.10); but that higher incidence was not statistically significant. There was significant evidence that age at diagnosis of breast cancer varied by mutation (P<.001), although only 8% of the variance in age at diagnosis could be explained by the specific mutation, and there was no evidence of family-specific effects. When the age at diagnosis of the breast cancer cases was examined by OCCR, cases associated with mutations in the OCCR had a significantly older mean age at diagnosis than was seen in those outside this region (48 years vs. 42 years; P=.0005).

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9585613      PMCID: PMC1377164          DOI: 10.1086/301885

Source DB:  PubMed          Journal:  Am J Hum Genet        ISSN: 0002-9297            Impact factor:   11.025


  19 in total

1.  The founder mutations 185delAG and 5382insC in BRCA1 and 6174delT in BRCA2 appear in 60% of ovarian cancer and 30% of early-onset breast cancer patients among Ashkenazi women.

Authors:  D Abeliovich; L Kaduri; I Lerer; N Weinberg; G Amir; M Sagi; J Zlotogora; N Heching; T Peretz
Journal:  Am J Hum Genet       Date:  1997-03       Impact factor: 11.025

2.  Generation of an integrated transcription map of the BRCA2 region on chromosome 13q12-q13.

Authors:  F J Couch; J M Rommens; S L Neuhausen; C Bélanger; M Dumont; K Abel; R Bell; S Berry; R Bogden; L Cannon-Albright; L Farid; C Frye; T Hattier; T Janecki; P Jiang; R Kehrer; J F Leblanc; J McArthur-Morrison; D Meney; Y Miki; Y Peng; C Samson; M Schroeder; S C Snyder; J Simard
Journal:  Genomics       Date:  1996-08-15       Impact factor: 5.736

3.  Could the 185delAG BRCA1 mutation be an ancient Jewish mutation?

Authors:  R B Bar-Sade; L Theodor; E Gak; A Kruglikova; G Hirsch-Yechezkel; B Modan; G Kuperstein; U Seligsohn; G Rechavi; E Friedman
Journal:  Eur J Hum Genet       Date:  1997 Nov-Dec       Impact factor: 4.246

Review 4.  Frequency of recurrent BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer families.

Authors:  P Tonin; B Weber; K Offit; F Couch; T R Rebbeck; S Neuhausen; A K Godwin; M Daly; J Wagner-Costalos; D Berman; G Grana; E Fox; M F Kane; R D Kolodner; M Krainer; D A Haber; J P Struewing; E Warner; B Rosen; C Lerman; B Peshkin; L Norton; O Serova; W D Foulkes; J E Garber
Journal:  Nat Med       Date:  1996-11       Impact factor: 53.440

5.  Population genetics of BRCA1 and BRCA2.

Authors:  C I Szabo; M C King
Journal:  Am J Hum Genet       Date:  1997-05       Impact factor: 11.025

6.  The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews.

Authors:  J P Struewing; P Hartge; S Wacholder; S M Baker; M Berlin; M McAdams; M M Timmerman; L C Brody; M A Tucker
Journal:  N Engl J Med       Date:  1997-05-15       Impact factor: 91.245

7.  Moderate frequency of BRCA1 and BRCA2 germ-line mutations in Scandinavian familial breast cancer.

Authors:  S Håkansson; O Johannsson; U Johansson; G Sellberg; N Loman; A M Gerdes; E Holmberg; N Dahl; N Pandis; U Kristoffersson; H Olsson; A Borg
Journal:  Am J Hum Genet       Date:  1997-05       Impact factor: 11.025

8.  Recurrent BRCA2 6174delT mutations in Ashkenazi Jewish women affected by breast cancer.

Authors:  S Neuhausen; T Gilewski; L Norton; T Tran; P McGuire; J Swensen; H Hampel; P Borgen; K Brown; M Skolnick; D Shattuck-Eidens; S Jhanwar; D Goldgar; K Offit
Journal:  Nat Genet       Date:  1996-05       Impact factor: 38.330

9.  Variation of risks of breast and ovarian cancer associated with different germline mutations of the BRCA2 gene.

Authors:  S A Gayther; J Mangion; P Russell; S Seal; R Barfoot; B A Ponder; M R Stratton; D Easton
Journal:  Nat Genet       Date:  1997-01       Impact factor: 38.330

10.  Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2.

Authors:  B B Roa; A A Boyd; K Volcik; C S Richards
Journal:  Nat Genet       Date:  1996-10       Impact factor: 38.330

View more
  50 in total

1.  Truncated BRCA2 is cytoplasmic: implications for cancer-linked mutations.

Authors:  B H Spain; C J Larson; L S Shihabuddin; F H Gage; I M Verma
Journal:  Proc Natl Acad Sci U S A       Date:  1999-11-23       Impact factor: 11.205

2.  Founder BRCA1/2 mutations among male patients with breast cancer in Israel.

Authors:  J P Struewing; Z M Coriaty; E Ron; A Livoff; M Konichezky; P Cohen; M B Resnick; B Lifzchiz-Mercerl; S Lew; J Iscovich
Journal:  Am J Hum Genet       Date:  1999-12       Impact factor: 11.025

3.  A single genetic origin for the G101W CDKN2A mutation in 20 melanoma-prone families.

Authors:  P Ciotti; J P Struewing; M Mantelli; A Chompret; M F Avril; P L Santi; M A Tucker; G Bianchi-Scarrà; B Bressac-de Paillerets; A M Goldstein
Journal:  Am J Hum Genet       Date:  2000-06-22       Impact factor: 11.025

4.  Geographic distribution of disease mutations in the Ashkenazi Jewish population supports genetic drift over selection.

Authors:  Neil Risch; Hua Tang; Howard Katzenstein; Josef Ekstein
Journal:  Am J Hum Genet       Date:  2003-02-24       Impact factor: 11.025

5.  Identification of a prostate cancer susceptibility locus on chromosome 7q11-21 in Jewish families.

Authors:  Danielle M Friedrichsen; Janet L Stanford; Sarah D Isaacs; Marta Janer; Bao-Li Chang; Kerry Deutsch; Elizabeth Gillanders; Suzanne Kolb; Katherine E Wiley; Michael D Badzioch; S Lilly Zheng; Patrick C Walsh; Gail P Jarvik; Leroy Hood; Jeffrey M Trent; William B Isaacs; Elaine A Ostrander; Jianfeng Xu
Journal:  Proc Natl Acad Sci U S A       Date:  2004-02-09       Impact factor: 11.205

6.  Haplotype analysis of the 185delAG BRCA1 mutation in ethnically diverse populations.

Authors:  Yael Laitman; Bing-Jian Feng; Itay M Zamir; Jeffrey N Weitzel; Paul Duncan; Danielle Port; Eswary Thirthagiri; Soo-Hwang Teo; Gareth Evans; Ayse Latif; William G Newman; Ruth Gershoni-Baruch; Jamal Zidan; Shani Shimon-Paluch; David Goldgar; Eitan Friedman
Journal:  Eur J Hum Genet       Date:  2012-07-04       Impact factor: 4.246

7.  On the origin and diffusion of BRCA1 c.5266dupC (5382insC) in European populations.

Authors:  Nancy Hamel; Bing-Jian Feng; Lenka Foretova; Dominique Stoppa-Lyonnet; Steven A Narod; Evgeny Imyanitov; Olga Sinilnikova; Laima Tihomirova; Jan Lubinski; Jacek Gronwald; Bohdan Gorski; Thomas v O Hansen; Finn C Nielsen; Mads Thomassen; Drakoulis Yannoukakos; Irene Konstantopoulou; Vladimir Zajac; Sona Ciernikova; Fergus J Couch; Celia M T Greenwood; David E Goldgar; William D Foulkes
Journal:  Eur J Hum Genet       Date:  2010-12-01       Impact factor: 4.246

8.  High proportion of novel mutations of BRCA1 and BRCA2 in breast/ovarian cancer patients from Castilla-León (central Spain).

Authors:  Mar Infante; Mercedes Durán; Eva Esteban-Cardeñosa; Cristina Miner; Eladio Velasco
Journal:  J Hum Genet       Date:  2006-06-07       Impact factor: 3.172

9.  Molecular and genealogical characterization of the R1443X BRCA1 mutation in high-risk French-Canadian breast/ovarian cancer families.

Authors:  Hélène Vézina; Francine Durocher; Martine Dumont; Louis Houde; Csilla Szabo; Martine Tranchant; Jocelyne Chiquette; Marie Plante; Rachel Laframboise; Jean Lépine; Heli Nevanlinna; Dominique Stoppa-Lyonnet; David Goldgar; Peter Bridge; Jacques Simard
Journal:  Hum Genet       Date:  2005-05-10       Impact factor: 4.132

10.  The Tyr978X BRCA1 mutation: occurrence in non-Jewish Iranians and haplotype in French-Canadian and non-Ashkenazi Jews.

Authors:  Lluís Quintana-Murci; Inbar Gal; Tangiz Bakhan; Hélène Quach; S Hamid Sayar; Ronit Shiri-Sverdlov; Ruth Gershoni Baruch; Ken McElreavey; Efrat Dagan; Steven Narod; Eitan Friedman
Journal:  Fam Cancer       Date:  2005       Impact factor: 2.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.